Table 3.
Association between statin use and risk of multiple myeloma by age group and gender, excluding the first 3 months of observation time and incorporating varying latency periods
| Latency period, months | N cases | Risk Ratio (95% CI)1 | P interaction |
|---|---|---|---|
| Age <70 years | |||
| 0 | 1215 | 1.19 (0.94, 1.51) | |
| 12 | 1132 | 1.18 (0.92, 1.51) | |
| 24 | 1006 | 1.07 (0.81, 1.41) | |
| 362 | 827 | 1.04 (0.76, 1.42) | |
| 482 | 663 | 0.95 (0.66, 1.38) | |
| 603 | 555 | 0.69 (0.43, 1.12) | |
| 724 | 437 | 0.73 (0.41, 1.30) | |
| Age ≥70 years | |||
| 0 | 1077 | 0.73 (0.57, 0.94) | 0.006 |
| 12 | 1023 | 0.81 (0.63, 1.04) | 0.04 |
| 24 | 929 | 0.76 (0.58, 0.99) | 0.08 |
| 362 | 804 | 0.78 (0.58, 1.05) | 0.19 |
| 482 | 702 | 0.67 (0.48, 0.94) | 0.18 |
| 603 | 587 | 0.71 (0.48, 1.05) | 0.95 |
| 724 | 477 | 0.87 (0.53, 1.40) | 0.66 |
| Males | |||
| 0 | 1253 | 0.97 (0.77, 1.24) | |
| 12 | 1186 | 1.02 (0.80, 1.29) | |
| 24 | 1066 | 0.97 (0.75, 1.25) | |
| 362 | 894 | 0.85 (0.63, 1.14) | |
| 482 | 746 | 0.69 (0.50, 0.97) | |
| 603 | 614 | 0.62 (0.42, 0.93) | |
| 724 | 493 | 0.70 (0.43, 1.14) | |
| Females | |||
| 0 | 1039 | 0.97 (0.76, 1.24) | 0.98 |
| 12 | 969 | 0.97 (0.75, 1.26) | 0.81 |
| 24 | 869 | 0.85 (0.64, 1.13) | 0.52 |
| 362 | 737 | 0.97 (0.71, 1.32) | 0.55 |
| 482 | 619 | 0.95 (0.66, 1.38) | 0.22 |
| 603 | 528 | 0.80 (0.51, 1.26) | 0.42 |
| 724 | 421 | 0.84 (0.49, 1.44) | 0.62 |
1
Risk Ratios from marginal structural models adjusted for age, index year, study site, gender, and time-updated coronary heart disease, hypertension, diabetes, non-steroidal anti-inflammatory drug use, diagnosed autoimmune disease, log(serum total cholesterol) and log (serum high-density lipoprotein) levels
2
Index years 1998–2000 combined in models
3
Index years 1998–2001 combined in models
4
Index years 1998–2003 combined in models